ONCE-DAILY
Qelbree®
viloxazine
extended-release capsules
100 mg 150 mg 200 mg

A NOVEL, NONSTIMULANT APPROACH for ADHD patients 6 years and older[1,2]

71% of patients were prescribed Qelbree because a change in their previous ADHD treatment was needed[3]

Today's fastest growing ADHD Rx Brand*



Patients who switched to Qelbree came from:

65% Stimulant sources[3]:
- Vyvanse®: 22%
- AMP ER/Adderall XR®: 15%
- MPH ER/Concerta®: 17%
- MPH IR: 6%
- AMP IR: 6%
- DEXMPH/Focalin®: 7%
- Other: 27%

35% Nonstimulant sources[3]:
- Atomoxetine/Strattera®: 61%
- Guanfacine/Intuniv®: 35%
- Other: 4%

*Branded ADHD products launched in last 5 years (as of September 2022).
†Prior ADHD treatment was defined as patients who switched to Qelbree, or for whom Qelbree was an add-on to current therapy (N=55,116 prescriptions).
Source: IQVIA NPA market dynamics data, 1/2022 to 12/2022.

Qelbree is covered across 75% of commercial lives[3]

INDICATION

Qelbree is indicated for the treatment of ADHD in patients 6 years and older.

IMPORTANT SAFETY INFORMATION

WARNING: SUICIDAL THOUGHTS AND BEHAVIORS

In clinical studies, higher rates of suicidal thoughts and behaviors were reported in patients with ADHD treated with Qelbree than in patients treated with placebo. Closely monitor all Qelbree-treated patients for clinical worsening and for emergence of suicidal thoughts and behaviors.

Please see Important Safety Information on page 2.

Abbreviations: ADHD, attention-deficit/hyperactivity disorder; AMP, mixed amphetamine salts; DEXMPH, dexmethylphenidate; ER, extended release; IR, immediate release; MPH, methylphenidate.

INDICATION

Qelbree is indicated for the treatment of ADHD in adults and pediatric patients 6 years and older.

IMPORTANT SAFETY INFORMATION

WARNING: SUICIDAL THOUGHTS AND BEHAVIORS

In clinical studies, higher rates of suicidal thoughts and behaviors were reported in patients with ADHD treated with Qelbree than in patients treated with placebo. Closely monitor all Qelbree-treated patients for clinical worsening and for emergence of suicidal thoughts and behaviors.

CONTRAINDICATIONS

- Concomitant administration of a monoamine oxidase inhibitor (MAOI), or dosing within 14 days after discontinuing an MAOI, because of an increased risk of hypertensive crisis
- Concomitant administration of sensitive CYP1A2 substrates or CYP1A2 substrates with a narrow therapeutic range

WARNINGS & PRECAUTIONS

- *Suicidal thoughts and behaviors*: Closely monitor all Qelbree-treated patients for clinical worsening and emergence of suicidal thoughts and behaviors, especially during the initial few months of drug therapy, and at times of dosage changes
- *Heart rate, blood pressure increases*: Qelbree can cause an increase in diastolic blood pressure and heart rate. Assess these measures prior to starting therapy, following increases in dosage, and periodically during therapy
- *Activation of mania or hypomania*: Noradrenergic drugs may induce a manic or mixed episode in patients with bipolar disorder. Prior to initiating treatment with Qelbree, screen patients to determine if they are at risk for bipolar disorder. Screening should include a detailed psychiatric history, including a personal or family history of suicide, bipolar disorder, and depression
- *Somnolence and fatigue*: Patients should not perform activities requiring mental alertness, such as operating a motor vehicle or hazardous machinery, due to potential somnolence (including sedation or lethargy) and fatigue, until they know how they will be affected by Qelbree

ADVERSE REACTIONS

The most common adverse reactions (≥5% and at least twice the rate of placebo for any dose) in patients 6 to 17 years were somnolence, decreased appetite, fatigue, nausea, vomiting, insomnia, and irritability, and in adults, insomnia, headache, somnolence, fatigue, nausea, decreased appetite, dry mouth, and constipation.

PREGNANCY

There is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to Qelbree during pregnancy. Healthcare providers are encouraged to register patients by calling the National Pregnancy Registry for Psychiatric Medications at 1-866-961-2388 or by visiting www.womensmentalhealth.org/preg.

REFERENCES: 1. Qelbree [package insert]. Rockville, MD: Supernus Pharmaceuticals, Inc. **2.** Food and Drug Administration. Novel drug approvals for 2021. May 13, 2022. Accessed January 9, 2023. https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2021. **3.** Data on file, Supernus Pharmaceuticals.

Please see full Prescribing Information, including Boxed Warning.

ONCE-DAILY Qelbree® viloxazine extended-release capsules 100 mg 150 mg 200 mg

Supernus® Pharmaceuticals